This inventor holds 6 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Fred Hutchinson Cancer Center, The University of Arizona, University of Washington. Active years: 1996-2020.
Company Filing History:
5 out of 309 
2 out of 1,055 
2 out of 2,169 
Years Active: 1996-2020
Title: Mark T Groudine: Innovator in Hemoglobinopathy Treatments
Introduction
Mark T Groudine is a prominent inventor based in Seattle, WA (US). He has made significant contributions to the field of medical research, particularly in the treatment of hemoglobinopathies. With a total of 6 patents to his name, Groudine's work has the potential to impact the lives of many individuals suffering from blood disorders.
Latest Patents
Groudine's latest patents include innovative compositions and methods for the treatment of hemoglobinopathies such as thalassemias and sickle cell disease. His work involves the use of endonucleases and CRISPR technology to disrupt specific gene regions and modify gene expression. This approach aims to correct mutations in the β-globin gene, which is crucial for the production of healthy red blood cells. Another notable patent focuses on boron-containing hormone analogs, which are designed to target hormonally responsive cells for imaging or therapeutic purposes. These compounds can be used to kill hormonally responsive tumor cells through a process known as boron neutron capture.
Career Highlights
Throughout his career, Groudine has worked with esteemed institutions such as the Fred Hutchinson Cancer Center and the University of Washington. His research has garnered attention for its innovative approaches to complex medical challenges.
Collaborations
Groudine has collaborated with notable figures in the field, including Leland H Hartwell and Sharon E Plon. These partnerships have furthered his research and contributed to advancements in medical science.
Conclusion
Mark T Groudine is a distinguished inventor whose work in hemoglobinopathy treatments showcases his commitment to improving patient outcomes. His innovative patents and collaborations highlight the importance of research in addressing critical health issues.